Catalent (NYSE:CTLT) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research report issued on Saturday. The brokerage set a “hold” rating on the stock.

Other equities research analysts also recently issued reports about the company. Robert W. Baird reissued a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. Barclays upped their target price on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, June 28th. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Nine investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Catalent has an average rating of “Hold” and a consensus target price of $59.83.

Catalent Stock Down 0.4 %

Shares of NYSE:CTLT opened at $60.45 on Friday. The company has a current ratio of 2.52, a quick ratio of 1.96 and a debt-to-equity ratio of 1.35. The firm has a 50 day simple moving average of $60.03 and a 200-day simple moving average of $57.65. The company has a market capitalization of $10.94 billion, a PE ratio of -9.91, a P/E/G ratio of 2.14 and a beta of 1.15. Catalent has a twelve month low of $31.80 and a twelve month high of $61.20.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The company had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion. On average, equities analysts predict that Catalent will post 0.95 EPS for the current fiscal year.

Insider Activity

In other news, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at $2,360,264.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the transaction, the senior vice president now owns 39,635 shares of the company’s stock, valued at approximately $2,360,264.25. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,410 shares of company stock valued at $732,680 in the last three months. 0.31% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Catalent

A number of institutional investors have recently made changes to their positions in the stock. Millennium Management LLC raised its stake in Catalent by 129.2% in the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after purchasing an additional 2,299,784 shares during the last quarter. Magnetar Financial LLC acquired a new position in shares of Catalent in the first quarter valued at approximately $56,429,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Catalent during the second quarter valued at approximately $29,172,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Catalent by 2,792.9% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock worth $29,150,000 after acquiring an additional 498,540 shares during the last quarter. Finally, Bank of Montreal Can grew its stake in Catalent by 222.0% in the 2nd quarter. Bank of Montreal Can now owns 644,123 shares of the company’s stock worth $36,219,000 after acquiring an additional 444,084 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.